Taysha Gene Therapies President, Head of R&D Sukumar Nagendran disposes of 200,000 common shares for $1.25 million

• Taysha Gene Therapies President and Head of R&D Sukumar Nagendran sold 200,000 common shares on July 10, 2026.
• Sale priced at USD 6.24 per share on a weighted-average basis.
• Post-transaction holding totaled 936,410 shares, held directly.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Taysha Gene Therapies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001665124-26-000013), on July 10, 2026, and is solely responsible for the information contained therein.